Literature DB >> 6462876

Formulation of a stable vidarabine phosphate injection.

M S Kwee, L M Stolk.   

Abstract

An injection fluid with vidarabine phosphate (37.5 mg/ml, pH 7.4) was formulated. After steam sterilization for 20 min at 120 degrees C a 6.1% degradation was observed. No significant (p greater than 0.05) degradation could be observed after heating in steam for 30 min at 100 degrees C and after storage for four months at 4 degrees C. From the results of an investigation of the degradation rate at elevated temperatures a negligible loss of content after a three years' storage period at 4 degrees C could be predicted.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6462876     DOI: 10.1007/bf01962998

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  5 in total

1.  Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate.

Authors:  J K Preiksaitis; B Lank; P K Ng; L Brox; G A LePage; D L Tyrrell
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

2.  Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humans.

Authors:  R J Whitley; B C Tucker; A W Kinkel; N H Barton; R F Pass; J D Whelchel; C G Cobbs; A G Diethelm; R A Buchanan
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

3.  Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP).

Authors:  I V Weller; M F Bassendine; A Craxi; M J Fowler; J Monjardino; H C Thomas; S Sherlock
Journal:  Gut       Date:  1982-09       Impact factor: 23.059

4.  Formulation of a stable vidarabine infusion fluid.

Authors:  L M Stolk; W Huisman; H D Nordemann; A Vyth
Journal:  Pharm Weekbl Sci       Date:  1983-04-29

5.  9-beta-D-arabinofuranosyladenine 5'-phosphate metabolism and excretion in humans.

Authors:  G A LePage; S R Naik; S B Katakkar; A Khaliq
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.